# Safety and Efficacy of Second Infusion of FAP iCDC in End-stage Dilated Cardiomyopathy

> **NCT07516288** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 5 (estimated)

## Conditions studied

- Dilated Cardiomyopathy (DCM)
- Heart Failure

## Interventions

- **BIOLOGICAL:** FAP immunosuppressive CAR-DC

## Key facts

- **NCT ID:** NCT07516288
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07516288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07516288, "Safety and Efficacy of Second Infusion of FAP iCDC in End-stage Dilated Cardiomyopathy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07516288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*